261
A GROUP of stubborn researchers determined to put their work at the service of the community overwhelmed by pandemic. Put the nephrologist student in Yokohama and a drug used for years as an anticoagulant but with the potential to be the most powerful antiviral for Covid-19. From this mix, the first clinical study in the world on nafamostat mesylate is born, which will be conducted in Padua thanks to a partnership between the University of Padua and the Hospital / University.
.